The estimated Net Worth of Rock Ventures Iii, L.P.Thir... is at least $43.2 Million dollars as of 12 November 2021. Rock Thir owns over 1,900,000 units of Nurix Therapeutics stock worth over $27,306,501 and over the last 4 years Rock sold NRIX stock worth over $15,922,000.
Rock has made over 1 trades of the Nurix Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Rock sold 1,900,000 units of NRIX stock worth $15,922,000 on 12 November 2021.
The largest trade Rock's ever made was selling 1,900,000 units of Nurix Therapeutics stock on 12 November 2021 worth over $15,922,000. On average, Rock trades about 380,000 units every 0 days since 2020. As of 12 November 2021 Rock still owns at least 1,148,780 units of Nurix Therapeutics stock.
You can see the complete history of Rock Thir stock trades at the bottom of the page.
Over the last 4 years, insiders at Nurix Therapeutics have traded over $1,236,800 worth of Nurix Therapeutics stock. The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall und Biomedical Innovation Maste.... On average, Nurix Therapeutics executives and independent directors trade stock every 15 days with the average trade being worth of $116,806. The most recent stock trade was executed by Christine Ring on 3 September 2024, trading 9,050 units of NRIX stock currently worth $42,173.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Nurix Therapeutics executives and other stock owners filed with the SEC include: